In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece
To study the evolution in the susceptibility of Enterobacter spp. in Crete, Greece from 2010 to 2015. Non-duplicate isolates were studied using automated systems. Phenotypic confirmatory tests were applied. A total of 939 Enterobacter isolates were included. Colistin was the most active antibiotic (...
Gespeichert in:
| Veröffentlicht in: | Future microbiology 2017-06, Vol.12 (8), p.683-693 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 693 |
|---|---|
| container_issue | 8 |
| container_start_page | 683 |
| container_title | Future microbiology |
| container_volume | 12 |
| creator | Maraki, Sofia Vardakas, Konstantinos Z Samonis, George Perdikis, Dimitrios Mavromanolaki, Viktoria Eirini Kofteridis, Diamantis P Falagas, Matthew E |
| description | To study the evolution in the susceptibility of Enterobacter spp. in Crete, Greece from 2010 to 2015.
Non-duplicate isolates were studied using automated systems. Phenotypic confirmatory tests were applied.
A total of 939 Enterobacter isolates were included. Colistin was the most active antibiotic (97.9%) followed by imipenem (96.1%), gentamicin (95.7%), tigecycline (91.8%), cefepime (89.4%), chloramphenicol (85.8%), fosfomycin (85.5%), trimethoprim/sulfamethoxazole (83.3%) and piperacillin/tazobactam (73.3%). Antibiotic resistance did not increase during the study period for most antibiotics. Lower susceptibility was observed among multidrug-resistant strains and carbapenem-nonsusceptible isolates. AmpC was the most common resistant mechanism (21%); carbapenemases (3.7%) and aminoglycoside-modifying enzymes (6.5%) were also detected.
A significant proportion of Enterobacter spp. was resistant to several antibiotics, most notably β-lactams. |
| doi_str_mv | 10.2217/fmb-2016-0216 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1902481857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2328810937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-c6cb886b861f68ae81b7677f67c7296ca80064ef72078b1c8cae767df48647023</originalsourceid><addsrcrecordid>eNpdkU1LJDEQhoMofu0e97oEvOzB1lS6J0kfl2FWBcGLnkM6U42R7qQ3SQtz9J-bZtSDp3ohDy-Vegj5BeyKc5DX_dhVnIGoGAdxQE5BNiW3HA6_MtQn5CylF8ZWClo4JidcrRomG3lK3u48fXU5BprmZHHKrnODyztq_JZGTC5l4y3S6Rl9yLsJE3We2uAzjlOIJu7opuQYOmPLoC6FweQ9Zejs3SvGtPQ9hzS5bIblYR0x4yW9iYgWf5Cj3gwJf37Mc_L0b_O4vq3uH27u1n_vK1tzyJUVtlNKdEpAL5RBBZ0UUvZCWslbYY1iTDTYS86k6sAqa7AA275RopGM1-fkz753iuH_jCnr0ZUfD4PxGOakoWW8UaBWsqAX39CXMEdfttO85koBa-uFqvaUjSGliL2eohvLRTQwvbjRxY1e3OjFTeF_f7TO3YjbL_pTRv0OY6GLtg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2328810937</pqid></control><display><type>article</type><title>In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece</title><source>MEDLINE</source><source>PubMed Central</source><creator>Maraki, Sofia ; Vardakas, Konstantinos Z ; Samonis, George ; Perdikis, Dimitrios ; Mavromanolaki, Viktoria Eirini ; Kofteridis, Diamantis P ; Falagas, Matthew E</creator><creatorcontrib>Maraki, Sofia ; Vardakas, Konstantinos Z ; Samonis, George ; Perdikis, Dimitrios ; Mavromanolaki, Viktoria Eirini ; Kofteridis, Diamantis P ; Falagas, Matthew E</creatorcontrib><description>To study the evolution in the susceptibility of Enterobacter spp. in Crete, Greece from 2010 to 2015.
Non-duplicate isolates were studied using automated systems. Phenotypic confirmatory tests were applied.
A total of 939 Enterobacter isolates were included. Colistin was the most active antibiotic (97.9%) followed by imipenem (96.1%), gentamicin (95.7%), tigecycline (91.8%), cefepime (89.4%), chloramphenicol (85.8%), fosfomycin (85.5%), trimethoprim/sulfamethoxazole (83.3%) and piperacillin/tazobactam (73.3%). Antibiotic resistance did not increase during the study period for most antibiotics. Lower susceptibility was observed among multidrug-resistant strains and carbapenem-nonsusceptible isolates. AmpC was the most common resistant mechanism (21%); carbapenemases (3.7%) and aminoglycoside-modifying enzymes (6.5%) were also detected.
A significant proportion of Enterobacter spp. was resistant to several antibiotics, most notably β-lactams.</description><identifier>ISSN: 1746-0913</identifier><identifier>EISSN: 1746-0921</identifier><identifier>DOI: 10.2217/fmb-2016-0216</identifier><identifier>PMID: 28540747</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Aminoglycoside antibiotics ; Aminoglycosides - pharmacology ; Anti-Bacterial Agents - pharmacology ; Antibiotic resistance ; Antibiotics ; Antimicrobial agents ; Automation ; Bacterial Proteins - biosynthesis ; beta-Lactamases - biosynthesis ; beta-Lactams - pharmacology ; Carbapenems - pharmacology ; Cefepime ; Cephalosporins - pharmacology ; Child ; Chloramphenicol ; Colistin ; Colistin - pharmacology ; Drug Resistance, Multiple, Bacterial ; E coli ; Enterobacter ; Enterobacter - drug effects ; Enterobacter - isolation & purification ; Enterobacter - physiology ; Enterobacteriaceae Infections - epidemiology ; Enterobacteriaceae Infections - microbiology ; Fosfomycin ; Gentamicin ; Greece - epidemiology ; Hospitals, University ; Humans ; Imipenem ; Internal medicine ; Microbial Sensitivity Tests ; Minocycline - analogs & derivatives ; Minocycline - pharmacology ; Multidrug resistance ; Nosocomial infections ; Oncology ; Pathogens ; Patients ; Pediatrics ; Penicillanic Acid - analogs & derivatives ; Penicillanic Acid - pharmacology ; Phenotype ; Phenotypes ; Piperacillin ; Piperacillin - pharmacology ; Sulfamethoxazole ; Tazobactam ; Tigecycline ; Trimethoprim ; β-Lactam antibiotics</subject><ispartof>Future microbiology, 2017-06, Vol.12 (8), p.683-693</ispartof><rights>Copyright Future Medicine Ltd Jun 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-c6cb886b861f68ae81b7677f67c7296ca80064ef72078b1c8cae767df48647023</citedby><cites>FETCH-LOGICAL-c321t-c6cb886b861f68ae81b7677f67c7296ca80064ef72078b1c8cae767df48647023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28540747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maraki, Sofia</creatorcontrib><creatorcontrib>Vardakas, Konstantinos Z</creatorcontrib><creatorcontrib>Samonis, George</creatorcontrib><creatorcontrib>Perdikis, Dimitrios</creatorcontrib><creatorcontrib>Mavromanolaki, Viktoria Eirini</creatorcontrib><creatorcontrib>Kofteridis, Diamantis P</creatorcontrib><creatorcontrib>Falagas, Matthew E</creatorcontrib><title>In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece</title><title>Future microbiology</title><addtitle>Future Microbiol</addtitle><description>To study the evolution in the susceptibility of Enterobacter spp. in Crete, Greece from 2010 to 2015.
Non-duplicate isolates were studied using automated systems. Phenotypic confirmatory tests were applied.
A total of 939 Enterobacter isolates were included. Colistin was the most active antibiotic (97.9%) followed by imipenem (96.1%), gentamicin (95.7%), tigecycline (91.8%), cefepime (89.4%), chloramphenicol (85.8%), fosfomycin (85.5%), trimethoprim/sulfamethoxazole (83.3%) and piperacillin/tazobactam (73.3%). Antibiotic resistance did not increase during the study period for most antibiotics. Lower susceptibility was observed among multidrug-resistant strains and carbapenem-nonsusceptible isolates. AmpC was the most common resistant mechanism (21%); carbapenemases (3.7%) and aminoglycoside-modifying enzymes (6.5%) were also detected.
A significant proportion of Enterobacter spp. was resistant to several antibiotics, most notably β-lactams.</description><subject>Aminoglycoside antibiotics</subject><subject>Aminoglycosides - pharmacology</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Automation</subject><subject>Bacterial Proteins - biosynthesis</subject><subject>beta-Lactamases - biosynthesis</subject><subject>beta-Lactams - pharmacology</subject><subject>Carbapenems - pharmacology</subject><subject>Cefepime</subject><subject>Cephalosporins - pharmacology</subject><subject>Child</subject><subject>Chloramphenicol</subject><subject>Colistin</subject><subject>Colistin - pharmacology</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>E coli</subject><subject>Enterobacter</subject><subject>Enterobacter - drug effects</subject><subject>Enterobacter - isolation & purification</subject><subject>Enterobacter - physiology</subject><subject>Enterobacteriaceae Infections - epidemiology</subject><subject>Enterobacteriaceae Infections - microbiology</subject><subject>Fosfomycin</subject><subject>Gentamicin</subject><subject>Greece - epidemiology</subject><subject>Hospitals, University</subject><subject>Humans</subject><subject>Imipenem</subject><subject>Internal medicine</subject><subject>Microbial Sensitivity Tests</subject><subject>Minocycline - analogs & derivatives</subject><subject>Minocycline - pharmacology</subject><subject>Multidrug resistance</subject><subject>Nosocomial infections</subject><subject>Oncology</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Penicillanic Acid - pharmacology</subject><subject>Phenotype</subject><subject>Phenotypes</subject><subject>Piperacillin</subject><subject>Piperacillin - pharmacology</subject><subject>Sulfamethoxazole</subject><subject>Tazobactam</subject><subject>Tigecycline</subject><subject>Trimethoprim</subject><subject>β-Lactam antibiotics</subject><issn>1746-0913</issn><issn>1746-0921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1LJDEQhoMofu0e97oEvOzB1lS6J0kfl2FWBcGLnkM6U42R7qQ3SQtz9J-bZtSDp3ohDy-Vegj5BeyKc5DX_dhVnIGoGAdxQE5BNiW3HA6_MtQn5CylF8ZWClo4JidcrRomG3lK3u48fXU5BprmZHHKrnODyztq_JZGTC5l4y3S6Rl9yLsJE3We2uAzjlOIJu7opuQYOmPLoC6FweQ9Zejs3SvGtPQ9hzS5bIblYR0x4yW9iYgWf5Cj3gwJf37Mc_L0b_O4vq3uH27u1n_vK1tzyJUVtlNKdEpAL5RBBZ0UUvZCWslbYY1iTDTYS86k6sAqa7AA275RopGM1-fkz753iuH_jCnr0ZUfD4PxGOakoWW8UaBWsqAX39CXMEdfttO85koBa-uFqvaUjSGliL2eohvLRTQwvbjRxY1e3OjFTeF_f7TO3YjbL_pTRv0OY6GLtg</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Maraki, Sofia</creator><creator>Vardakas, Konstantinos Z</creator><creator>Samonis, George</creator><creator>Perdikis, Dimitrios</creator><creator>Mavromanolaki, Viktoria Eirini</creator><creator>Kofteridis, Diamantis P</creator><creator>Falagas, Matthew E</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>201706</creationdate><title>In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece</title><author>Maraki, Sofia ; Vardakas, Konstantinos Z ; Samonis, George ; Perdikis, Dimitrios ; Mavromanolaki, Viktoria Eirini ; Kofteridis, Diamantis P ; Falagas, Matthew E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-c6cb886b861f68ae81b7677f67c7296ca80064ef72078b1c8cae767df48647023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aminoglycoside antibiotics</topic><topic>Aminoglycosides - pharmacology</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Automation</topic><topic>Bacterial Proteins - biosynthesis</topic><topic>beta-Lactamases - biosynthesis</topic><topic>beta-Lactams - pharmacology</topic><topic>Carbapenems - pharmacology</topic><topic>Cefepime</topic><topic>Cephalosporins - pharmacology</topic><topic>Child</topic><topic>Chloramphenicol</topic><topic>Colistin</topic><topic>Colistin - pharmacology</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>E coli</topic><topic>Enterobacter</topic><topic>Enterobacter - drug effects</topic><topic>Enterobacter - isolation & purification</topic><topic>Enterobacter - physiology</topic><topic>Enterobacteriaceae Infections - epidemiology</topic><topic>Enterobacteriaceae Infections - microbiology</topic><topic>Fosfomycin</topic><topic>Gentamicin</topic><topic>Greece - epidemiology</topic><topic>Hospitals, University</topic><topic>Humans</topic><topic>Imipenem</topic><topic>Internal medicine</topic><topic>Microbial Sensitivity Tests</topic><topic>Minocycline - analogs & derivatives</topic><topic>Minocycline - pharmacology</topic><topic>Multidrug resistance</topic><topic>Nosocomial infections</topic><topic>Oncology</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Penicillanic Acid - pharmacology</topic><topic>Phenotype</topic><topic>Phenotypes</topic><topic>Piperacillin</topic><topic>Piperacillin - pharmacology</topic><topic>Sulfamethoxazole</topic><topic>Tazobactam</topic><topic>Tigecycline</topic><topic>Trimethoprim</topic><topic>β-Lactam antibiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maraki, Sofia</creatorcontrib><creatorcontrib>Vardakas, Konstantinos Z</creatorcontrib><creatorcontrib>Samonis, George</creatorcontrib><creatorcontrib>Perdikis, Dimitrios</creatorcontrib><creatorcontrib>Mavromanolaki, Viktoria Eirini</creatorcontrib><creatorcontrib>Kofteridis, Diamantis P</creatorcontrib><creatorcontrib>Falagas, Matthew E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Future microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maraki, Sofia</au><au>Vardakas, Konstantinos Z</au><au>Samonis, George</au><au>Perdikis, Dimitrios</au><au>Mavromanolaki, Viktoria Eirini</au><au>Kofteridis, Diamantis P</au><au>Falagas, Matthew E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece</atitle><jtitle>Future microbiology</jtitle><addtitle>Future Microbiol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>12</volume><issue>8</issue><spage>683</spage><epage>693</epage><pages>683-693</pages><issn>1746-0913</issn><eissn>1746-0921</eissn><abstract>To study the evolution in the susceptibility of Enterobacter spp. in Crete, Greece from 2010 to 2015.
Non-duplicate isolates were studied using automated systems. Phenotypic confirmatory tests were applied.
A total of 939 Enterobacter isolates were included. Colistin was the most active antibiotic (97.9%) followed by imipenem (96.1%), gentamicin (95.7%), tigecycline (91.8%), cefepime (89.4%), chloramphenicol (85.8%), fosfomycin (85.5%), trimethoprim/sulfamethoxazole (83.3%) and piperacillin/tazobactam (73.3%). Antibiotic resistance did not increase during the study period for most antibiotics. Lower susceptibility was observed among multidrug-resistant strains and carbapenem-nonsusceptible isolates. AmpC was the most common resistant mechanism (21%); carbapenemases (3.7%) and aminoglycoside-modifying enzymes (6.5%) were also detected.
A significant proportion of Enterobacter spp. was resistant to several antibiotics, most notably β-lactams.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>28540747</pmid><doi>10.2217/fmb-2016-0216</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-0913 |
| ispartof | Future microbiology, 2017-06, Vol.12 (8), p.683-693 |
| issn | 1746-0913 1746-0921 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1902481857 |
| source | MEDLINE; PubMed Central |
| subjects | Aminoglycoside antibiotics Aminoglycosides - pharmacology Anti-Bacterial Agents - pharmacology Antibiotic resistance Antibiotics Antimicrobial agents Automation Bacterial Proteins - biosynthesis beta-Lactamases - biosynthesis beta-Lactams - pharmacology Carbapenems - pharmacology Cefepime Cephalosporins - pharmacology Child Chloramphenicol Colistin Colistin - pharmacology Drug Resistance, Multiple, Bacterial E coli Enterobacter Enterobacter - drug effects Enterobacter - isolation & purification Enterobacter - physiology Enterobacteriaceae Infections - epidemiology Enterobacteriaceae Infections - microbiology Fosfomycin Gentamicin Greece - epidemiology Hospitals, University Humans Imipenem Internal medicine Microbial Sensitivity Tests Minocycline - analogs & derivatives Minocycline - pharmacology Multidrug resistance Nosocomial infections Oncology Pathogens Patients Pediatrics Penicillanic Acid - analogs & derivatives Penicillanic Acid - pharmacology Phenotype Phenotypes Piperacillin Piperacillin - pharmacology Sulfamethoxazole Tazobactam Tigecycline Trimethoprim β-Lactam antibiotics |
| title | In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T10%3A49%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20susceptibility%20and%20resistance%20phenotypes%20in%20contemporary%20Enterobacter%20isolates%20in%20a%20university%20hospital%20in%20Crete,%20Greece&rft.jtitle=Future%20microbiology&rft.au=Maraki,%20Sofia&rft.date=2017-06&rft.volume=12&rft.issue=8&rft.spage=683&rft.epage=693&rft.pages=683-693&rft.issn=1746-0913&rft.eissn=1746-0921&rft_id=info:doi/10.2217/fmb-2016-0216&rft_dat=%3Cproquest_cross%3E2328810937%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2328810937&rft_id=info:pmid/28540747&rfr_iscdi=true |